360 Stem Cell & Regenerative Medicine Newsletter - July 29, 2014

 weSRCH's Best of the Internet Award

360 Stem Cell & Regenerative Medicine Newsletter - July 29, 2014

Featured video- John Hopkins Medicine: Programming Cancer Cells to Self-Destruct |Science Out of the Box
Programming Cancer Cells to Self-Destruct |Science Out of the Box
Making complex biomedical science completely understandable, Johns Hopkins biomedical engineer Dr. Jordan Green uses dominoes and balloons to illustrate a goal of his research: making nanoparticles that could program cancer cells to self-destruct.
Whitehead Institute: Researchers create “naïve” pluripotent human embryonic stem cells
Researchers at MIT have discovered how to manipulate and maintain human ESCs in a “naïve” or base pluripotent state similar to that of mouse ESCs without the use of any reprogramming factors. MIT professor of biology Dr. Rudolf Jaenisch stated, “We have discovered a new pathway to generate something we believe is a totally different state of pluripotency in human ESCs that is very close to the mouse naïve state. These cells may be essential for ESC technology, and that is an area we’re looking forward to investigating. Now the big question for us is, does this state exist in vivo in embryos? Right now, we don’t know, and that is a very interesting line of research.” The work is described in the journal Cell Stem Cell. (Dr. Jaenisch is one of the founding members of the GPI Science Advisory Board).
Karolinska Institutet: Stem cells from nerves form teeth
Researchers in Sweden discovered that stem cells inside the soft tissues of the tooth come from nerves. These findings contribute to brand new knowledge of how teeth are formed, how they grow and how they are able to self-repair. The researchers assert that discovery of this new type of stem cells is an important step towards the knowledge and technology will be required to grow new teeth in adults. The research was published in Nature.
UCSF: Stem cell advance may increase efficiency of tissue regeneration
Seeking to understand the roadblocks to reprogramming cells, scientists at UC San Francisco identified some biochemical pathways inhibiting the necessary reprogramming of gene activity in adult human cells. Removing these barriers increased the efficiency of stem-cell production. The findings were reported in Cell.
New Scientist: 'Epigenetic' gene tweaks seem to trigger cancer
Methylation can be a primary cause of tumors. Utilizing mouse embryonic stem cells, researchers at Baylor College of Medicine have demonstrated the “first direct evidence that switching off certain genes – something that can be caused by our lifestyle or the environment we live in – can trigger tumors, without mutating the DNA itself.” The research was published in The Journal of Clinical Investigation.
Kevin McCormick (CIRM): Will current clinical trial mean the end of sickle cell disease?
CIRM’s director of communications, Kevin McCormick writes in the San Francisco Bay View about a clinical trial funded by the California Institute for Regenerative Medicine seeking a cure for sickle cell disease. Dr. Donald Kohn, a professor at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA leads the study. A patient’s perspective is featured in the article.
Bioresearch Online: Two Australian patients reported HIV-free after stem cell treatments for cancer
“One of the patients was afflicted with non-Hodgkin’s lymphoma and received a bone marrow transplant as treatment in 2011. The donor who gave his replacement stem cells happened to carry a copy of the gene believed to protect against HIV. The second patient received a similar stem cell transplant as treatment for leukemia in 2012.” David Cooper, Director of the Kirby Institute at the University of New South Wales in Sydney, led the research and presented his findings at the 20th International AIDS Conference.
The Australian: Mesoblast sows the seeds for stem cell success
In this profile piece about Mesoblast, the company’s chief executive Silviu Itescu says the regenerative medicine company is on track to launch the world’s first stem cell therapy product in Japan next year and this could be followed by a possible US launch in 2016.
Sydney Morning Herald: Stem cell treatment warnings after Australian woman dies in Russia
Brisbane mother-of-two Kellie van Meurs traveled to Moscow for treatment for a rare neurological disorder called Stiff Person Syndrome. She died from a heart attack while undergoing the controversial treatment on July 19. Her death, and the continued marketing of stem cell tourism by certain groups, prompted warnings by Australian authorities that many of the therapies offered are untested and not accepted by mainstream science. Stem Cells Australia's head of education, ethics, law and community awareness Dr. Megan Munsie said a proliferation of private clinics combined with a growing consumer base was a potentially dangerous mix.
Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus has exciting news about CRISPR Therapeutics and other cutting-edge companies
The UK continues to be a hotbed of regenerative medicine and biotechnology activity and investment. According to a SBC media release, “Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage bioscience technology and company development, and building a thriving community. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the former East of England Development Agency. Consisting of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies, from virtual and start-up firms to those which are more established, as well as other organizations.”

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute

Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter

About GPI

The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn

Bringing our World Together- the World Stem Cell Summit
Domain: Medical
Category: Biology

Recent Newsletters

Linley Newsletter: August 8, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #664 August 8, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

08 August, 2019

Linley Newsletter: August 1, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #663 August 1, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

01 August, 2019

Linley Newsletter: July 25, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #662 July 25, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry

25 July, 2019